SOURCE: Streetwise Reports

Streetwise Reports

February 12, 2016 09:00 ET

CorMedix's CEO Randy Milby Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - February 12, 2016) -  Patients on dialysis and cancer patients with indwelling catheters live with the possibility of contracting drug-resistant infections that can become more life threatening than their primary diseases. CorMedix Inc. (NYSE MKT: CRMD) is developing a platform that has shown impressive results in preventing serious bloodstream infections. In this interview with The Life Sciences Report, CorMedix CEO Randy Milby addresses his company's science, pipeline and market opportunity. Chief Scientific Officer and Cofounder Antony Pfaffle, an internist who practiced nephrology, joins the conversation to relate his experience managing chronically ill patients undergoing catheter-based therapies in the critical care setting.

The Life Sciences Report : Quality and quality assurance are becoming major focuses in hospitals these days. It starts with making sure employees are washing their hands, and it goes to the operating room, where quality assurance managers want personnel to perform checklists before procedures are done. Quality is about preventing unnecessary morbidity and mortality, and making sure the healthcare system is getting value for the reimbursements by payers. Do you see CorMedix, with Neutrolin and its taurolidine-based platform, fitting into that model of prevention and quality assurance?

Randy Milby: Absolutely. We believe our platform fits into the concept of infection prevention very nicely, and we believe we can become an overall anti-infective solution. The FDA must also believe we're capable of becoming an important component because it granted Neutrolin QIDP designation. Neutrolin will be a nice fit into that concept, and into the armamentarium that enables it.

TLSR: You just began your Phase 3 trial with Neutrolin in December 2015. I'm noting that it's powered quite well. You will eventually have 632 patients enrolled in this study, and it is double-blind and placebo-controlled. Will there be an interim look at the data?

RM: We hope to complete the enrollment by…

Continue reading this interview: CorMedix Transformative Anti-Infective Technology for Catheters Developed to Decrease Serious Drug-Resistant Infections: CEO Randy Milby

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

DISCLOSURE:

CorMedix Inc. is a sponsor of Streetwise Reports. Randy Milby and Antony Pfaffle had final approval of the content and are wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Milby and Dr. Pfaffle, and not of Streetwise Reports or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Please see Streetwise Reports' terms of use and full legal disclaimer.

Contact Information